Iluvien recommended for funding in UK

NICE has recommended funding for Iluvien in the UK for non-infectious uveitis affecting the posterior segment (NIPU).

A NICE recommendation for funding signifies that the NHS will pay for Iluvien prescriptions for the treatment of NIPU as part of its offering.

Iluvien is also funded for the treatment of diabetic macular edema (DME) in the UK.

“We continue to execute on our plans to launch Iluvien’s new indication in Europe for non-infectious posterior uveitis, a significant and, we believe, poorly-served medical need,” said Rick Eiswirth, President and CEO of Alimera Sciences.

“The positive funding recommendation from NICE facilitates patient access in England and Wales for this second indication with funding from the NHS.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news